



Dr. Joost Kreijtz

Short bio:

Joost Kreijtz is CEO (Europe) of Trained Therapeutix Discovery, a biotech company with its R&D headquarters in the Netherlands. TTxD develops nanomedicines that target innate immunity at its source to unlock the full potential of immunotherapy in oncology and inflammatory diseases. Trained as a biomedical scientist with a focus on immunology, Joost brings over 15 years of drug development experience, specializing in translating immunotherapies from concept to clinic and building high-performing biotech teams and companies.

Presentation title:

Deploying nanomedicine to unleash the body's innate defense against disease

Abstract:

Adaptive immunotherapies have reshaped the treatment landscape in oncology and immune-mediated disease. However, targeting innate immunity can fully realize the potential of immunotherapy. Increasing attention is therefore shifting toward myeloid cells as a therapeutic entry point. The unique therapeutic opportunity lies with myeloid progenitor cells given their central role in shaping downstream inflammatory and anti-tumor immune responses. Trained Therapeutix Discovery (TTxD) is advancing a first-in-class approach to innate immunity nanomedicine by modulating myeloid (progenitor) cells in vivo at their origin. This strategy aims to enable durable and tunable innate immune responses across multiple indications including solid tumor (RIDE-001 program) and inflammatory diseases (RIDE-002 program).